Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

409 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
PDK1-Dependent Metabolic Reprogramming Dictates Metastatic Potential in Breast Cancer.
Dupuy F, Tabariès S, Andrzejewski S, Dong Z, Blagih J, Annis MG, Omeroglu A, Gao D, Leung S, Amir E, Clemons M, Aguilar-Mahecha A, Basik M, Vincent EE, St-Pierre J, Jones RG, Siegel PM. Dupuy F, et al. Among authors: clemons m. Cell Metab. 2015 Oct 6;22(4):577-89. doi: 10.1016/j.cmet.2015.08.007. Epub 2015 Sep 10. Cell Metab. 2015. PMID: 26365179 Free article.
Prevalence of overt metastases in locally advanced breast cancer.
Al-Husaini H, Amir E, Fitzgerald B, Wright F, Dent R, Fralick J, Clemons M. Al-Husaini H, et al. Among authors: clemons m. Clin Oncol (R Coll Radiol). 2008 Jun;20(5):340-4. doi: 10.1016/j.clon.2008.03.006. Clin Oncol (R Coll Radiol). 2008. PMID: 18420394
Predicting benefit from fulvestrant in pretreated metastatic breast cancer patients.
Freedman O, Amir E, Dranitsaris G, Napolskikh J, Kumar R, Fralick M, Chia S, Petrella T, Dent S, Tonkin K, Ahmad I, Rayson D, Clemons M. Freedman O, et al. Among authors: clemons m. Breast Cancer Res Treat. 2009 Nov;118(2):377-83. doi: 10.1007/s10549-009-0452-8. Epub 2009 Jun 24. Breast Cancer Res Treat. 2009. PMID: 19551499
A randomized trial exploring the biomarker effects of neoadjuvant sequential treatment with exemestane and anastrozole in post-menopausal women with hormone receptor-positive breast cancer.
Freedman OC, Amir E, Hanna W, Kahn H, O'Malley F, Dranitsaris G, Cole DE, Verma S, Folkerd E, Dowsett M, Clemons M. Freedman OC, et al. Among authors: clemons m. Breast Cancer Res Treat. 2010 Jan;119(1):155-61. doi: 10.1007/s10549-009-0523-x. Breast Cancer Res Treat. 2010. PMID: 19731013 Clinical Trial.
409 results